title: Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus.
abstract: OBJECTIVE
  Endoscopic therapy is increasingly being used in the treatment of high-grade intraepithelial neoplasia (HGIN) and mucosal adenocarcinoma (BC) in patients with Barrett's oesophagus. This report provides 5 year follow-up data from a large prospective study investigating the efficacy and safety of endoscopic treatment in these patients and analysing risk factors for recurrence.
  
  
  METHODS
  Prospective case series.
  
  
  METHODS
  Academic tertiary care centre.
  
  
  METHODS
  Between October 1996 and September 2002, 61 patients with HGIN and 288 with BC were included (173 with short-segment and 176 with long-segment Barrett's oesophagus) from a total of 486 patients presenting with Barrett's neoplasia. Patients with submucosal or more advanced cancer were excluded.
  
  
  METHODS
  Endoscopic therapy.
  
  
  METHODS
  Rate of complete remission and recurrence rate, tumour-associated death.
  
  
  RESULTS
  Endoscopic resection was performed in 279 patients, photodynamic therapy in 55, and both procedures in 13; two patients received argon plasma coagulation. The mean follow-up period was 63.6 (SD 23.1) months. Complete response (CR) was achieved in 337 patients (96.6%); surgery was necessary in 13 (3.7%) after endoscopic therapy failed. Metachronous lesions developed during the follow-up in 74 patients (21.5%); 56 died of concomitant disease, but none died of BC. The calculated 5 year survival rate was 84%. The risk factors most frequently associated with recurrence were piecemeal resection, long-segment Barrett's oesophagus, no ablative therapy of Barrett's oesophagus after CR, time until CR achieved >10 months and multifocal neoplasia.
  
  
  CONCLUSIONS
  This study showed that endoscopic therapy was highly effective and safe, with an excellent long-term survival rate. The risk factors identified may help stratify patients who are at risk for recurrence and those requiring more intensified follow-up.
authors.affiliation: Department of Internal Medicine II, HSK Wiesbaden, Ludwig-Erhard-Strasse 100, 65199 Wiesbaden, Germany.
authors.forename: O
authors.initials: O
authors.lastname: Pech
authors.forename: A
authors.initials: A
authors.lastname: Behrens
authors.forename: A
authors.initials: A
authors.lastname: May
authors.forename: L
authors.initials: L
authors.lastname: Nachbar
authors.forename: L
authors.initials: L
authors.lastname: Gossner
authors.forename: T
authors.initials: T
authors.lastname: Rabenstein
authors.forename: H
authors.initials: H
authors.lastname: Manner
authors.forename: E
authors.initials: E
authors.lastname: Guenter
authors.forename: J
authors.initials: J
authors.lastname: Huijsmans
authors.forename: M
authors.initials: M
authors.lastname: Vieth
authors.forename: M
authors.initials: M
authors.lastname: Stolte
authors.forename: C
authors.initials: C
authors.lastname: Ell
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology / Q000601:surgery*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001471:Barrett Esophagus / Q000601:surgery*; D002278:Carcinoma in Situ / Q000473:pathology / Q000601:surgery*; D004812:Epidemiologic Methods; D004938:Esophageal Neoplasms / Q000473:pathology / Q000601:surgery*; D004945:Esophagoscopy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011230:Precancerous Conditions / Q000601:surgery*; D016896:Treatment Outcome